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acid (DA), di-methyl sulphoxide (DMSO), phospholipase A2-Activating Peptide (PLAP), polyacrylamide 
gel electrophoresis (PAGE), propylisopropylacetic acid (PIA), prostaglandin (PG), valproic acid (VPA), 
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Abstract  
 
Many neurodegenerative diseases present the loss of synapses as a common pathological feature. Here we 
have employed an in vitro model for synaptic loss to investigate the molecular mechanism of a therapeutic 
treatment, valproic acid (VPA). We show that amyloid-β (Aβ), isolated from patient tissue and thought to 
be the causative agent of Alzheimer’s disease, caused the loss of synaptic proteins including synaptophysin, 
synapsin-1 and cysteine-string protein from cultured mouse neurons. Aβ-induced synapse damage was 
reduced by pre-treatment with physiologically relevant concentrations of VPA (10 μM) and a structural 
variant propylisopropylacetic acid (PIA). These drugs also reduced synaptic damage induced by other 
neurodegenerative-associated proteins α-synuclein, linked to Lewy body dementia and Parkinson’s disease, 
and the prion-derived peptide PrP82-146. Consistent with these effects, synaptic vesicle recycling was also 
inhibited by these proteins and protected by VPA and PIA. We show a mechanism for this damage through 
aberrant activation of cytoplasmic phospholipase A2 (cPLA2) that is reduced by both drugs. Furthermore, 
Aβ-dependent cPLA2 activation correlates with its accumulation in lipid rafts, and is likely to be caused by 
elevated cholesterol (stabilising rafts) and decreased cholesterol ester levels, and this mechanism is reduced 
by VPA and PIA. Such observations suggest that VPA and PIA may provide protection against synaptic 
damage that occurs during Alzheimer’s and Parkinson’s and prion diseases. 
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Introduction 
 
Neurodegenerative diseases comprise a disparate group of conditions involving a common loss of synaptic 
function. These conditions provide a huge societal impact, with a large number of people experiencing 
severe symptoms. Understanding the molecular processes involved in these diseases and the development 
of either existing treatments (with new indications) or new treatment thus provides an urgent need. 
Alzheimer’s disease is amongst the most important of these diseases, where the progressive loss of neuronal 
function is associated with the production of neurotoxic amyloid-β (Aβ) peptides that are cleaved from the 
C terminal of the amyloid precursor protein (Hardy, 2006). The clinical symptoms in Alzheimer’s disease 
are caused by the loss or dysfunction of synapses (Walsh and Selkoe, 2004), and the best correlate of the 
degree of dementia in Alzheimer’s disease patients is a reduction in synaptic density and the loss of synaptic 
proteins including synaptophysin, cysteine-string protein (CSP), vesicle-associated membrane protein 
(VAMP)-1 and synapsin-1 (Reddy et al., 2005; Terry et al., 1991). Yet the mechanism leading to synaptic 
loss remains unclear. 
 
Other neurodegenerative disorders are also associated with synaptic loss, including Lewy body dementia, 
Parkinson’s disease (Kramer and Schulz-Schaeffer, 2007) and prion diseases (Ferrer, 2002). In vitro models 
for these diseases employ aggregated α-synuclein protein (αSN) that accumulates at synaptic terminals, or 
the prion-derived peptide PrP82-146 (Salmona et al., 2003) to cause synaptic damage in cultured neurons 
(Bate et al., 2010). Such neurotoxic peptides have been shown to cause a reduction in synaptic density as 
determined by quantifying the amounts of synaptophysin and CSP. The molecular and cellular mechanisms 
involved in αSN and PrP82-146-dependent synaptic degeneration also remains poorly understood. 
 
To bypass the long and expensive process of developing new therapeutic agents for neurological disorders 
(Wegener and Rujescu 2013), it may be possible to re-purpose compounds with established safety profiles. 
One such compound, valproic acid (2-propylpentanoic acid (VPA)), is a short branched-chain fatty acid 
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that has been proposed to have potential therapeutic role in Alzheimer’s disease treatment (Qing et al., 
2008a) and neuroprotection (Zhang et al., 2014). VPA is primarily used for the treatment of epilepsy and 
bipolar disorder treatment, although it has numerous molecular mechanisms and effects (Terbach and 
Williams, 2009), including the inhibition of cPLA2 (Bazinet et al., 2006) and the regulation of lipid 
homeostasis (Elphick et al., 2012). Here we show that synapse damage caused by Aβ, αSN and PrP82-146 
is reduced by VPA and a structural derivative (propylisopropylacetic acid (PIA)). We show the mechanism 
for this neuroprotective effect occurs through the inhibition of Aβ, αSN and PrP82-146 dependent 
cytoplasmic phospholipase A2 (PLA2) hyperactivation. We further demonstrate that this mechanism of Aβ-
induced toxicity is associated with increased translocation of cPLA2 to lipid rafts (leading to 
hyperactivation), since Aβ causes a dose-dependent increase in cholesterol and a reduction in cholesterol 
esters, and that this process is reduced by VPA and PIA. 
 
Materials and Methods 
 
Brain extracts – Soluble brain extracts from an Alzheimer’s patient containing Aβ of similar in size and 
potency to the Aβ species previously isolated from the brains of Alzheimer’s disease patients (Shankar et 
al., 2008) were used. Extracts were derived from the temporal lobe of a 78 year old female with a clinical, 
and pathologically-confirmed, diagnosis of Alzheimer’s disease, supplied by Asterand, an international 
supplier of human tissue. Brain tissue was cut into pieces of approximately 100 mg and added to 2 ml tubes 
containing lysing matrix D beads (Q-Bio). Neurobasal medium containing B27 components was added so 
that there was the equivalent of 100 mg brain tissue/ml. The tubes were shaken for 10 minutes (Disruptor 
genie, Scientific Instruments). This process was performed 3 times before tubes were centrifuged at 16,000 
x g for 10 minutes to remove cell debris. Soluble material was prepared by passage through a 50 kDa filter 
(Sartorius) (16,000 x g for 30 minutes) to remove any protease activity. The amounts of Aβ in each soluble 
extract were measured by ELISA (see below) and the supernatant aliquoted and stored at -80oC. For 
immunoblot analysis, brain extracts were mixed with an equal volume of 0.5% NP-40, 5 mM CHAPS, 50 
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mM Tris, pH 7.4 and separated by polyacrylamide gel electrophoresis (PAGE). Proteins were transferred 
onto a PVDF membrane by semi-dry blotting and blocked using 10% milk powder. Aβ was detected by 
incubation with mAb 6E10 (Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and enhanced 
chemiluminescence. The amounts of Aβ42 in preparations were determined by ELISA. 
Size exclusion chromatography (SEC) – Soluble brain extracts were concentrated using desalting 
columns (3 kDa filter – Sartorius). These preparations were injected into a Superdex 75 PC column 
(separates peptides ranging from 3 kDa to 70 kDa) (GE Healthcare) and eluted at a rate of 0.2 ml/minute. 
Fractions were collected and tested by Aβ ELISA (see below).   
Immunodepletions - Brain extracts were incubated with 0.1 μg/ml mAb 4G8 (reactive with amino acids 
17-24 of Aβ) or isotype controls (mock depletions) and incubated at 4oC on rollers for 1 hour. Protein G 
microbeads were added (10 µl/ml) (Sigma) for 30 minutes and protein G bound-antibody complexes 
removed by centrifugation.  
Primary neuronal cultures - Primary cortical neurons were prepared from the brains of mouse embryos 
(day 15.5) after mechanical dissociation. Neurons were plated at 5 x 105 cells/well in 48 well plates in Hams 
F12 containing 5% foetal calf serum for 2 hrs. Cultures were shaken (600 r.p.m for 5 mins) and non-
adherent cells removed by 2 washes in phosphate buffered saline (PBS). Neurons were subsequently grown 
in neurobasal medium containing B27 components (PAA) for 10 days.  Immunostaining showed that after 
10 days culture less than 5% of the viable cells stained for glial fibrillary acidic protein or F4/80 (astrocytes 
or microglial cells).  Neurons were subsequently pre-treated with test compounds including VPA, PIA and 
decanoic acid for 1 hour before the addition of test samples including Aβ, recombinant human α-synuclein 
(αSN) (Sigma), PrP82-146 (Salmona et al., 2003)(a gift from Professor M Salmona, Milan) or 
Phospholipase A2-Activating Peptide (PLAP) (Bachem) for 24 hours. All experiments were performed in 
accordance with European regulations (European community Council Directive, 1986, 56/609/EEC) and 
approved by the local authority veterinary service/ethical committee. 
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Cell extracts -  Treated cells were washed twice in PBS and homogenised in 10 mM Tris-HCl, 100 mM 
NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate and 0.2% SDS at 106 cells/ml. Mixed 
protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, Aprotinin, Leupeptin, 
Bestatin, Pepstatin A and E-46) (Sigma) and a phosphatase inhibitor cocktail including PP1, PP2A, 
microcystin LR, cantharidin and p-bromotetramisole (Sigma) were added and nuclei and large fragments 
were removed by centrifugation (1000 x g for 5 minutes).  
 
Western Blotting - Samples were mixed with Laemmli buffer containing β-mercaptoethanol, heated to 
95oC for 5 minutes and proteins were separated by electrophoresis on 15% polyacrylamide gels. Proteins 
were transferred onto a Hybond-P polyvinylidene difluoride membrane by semi-dry blotting. Membranes 
were blocked using 10% milk powder; synapsin-1 was detected with goat polyclonal (Santa Crux Biotech), 
synaptophysin with MAB368 (Abcam), VAMP-1 with mAb 4H302 (Abcam), caveolin with rabbit 
polyclonal antibodies (Upstate) and CSP with rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz). These 
were visualised using combinations of biotinylated anti-mouse/goat/rat/rabbit IgG (Sigma), extravidin-
peroxidase and enhanced chemiluminescence.  
Synaptophysin ELISA. The amount of synaptophysin in neuronal extracts was measured by ELISA as 
described (Bate et al., 2010). Maxisorb immunoplates (Nunc) were coated with a mouse anti-synaptophysin 
mAb (MAB368 - Chemicon) as a capture antibody and bound synaptophysin was detected using rabbit 
polyclonal anti-synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG (Abcam), extravidin-
alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate (pNPP) solution (Sigma). Absorbance was 
measured on a microplate reader at 405 nm. Samples were expressed as “units synaptophysin” where 100 
units was defined as the amount of synaptophysin in 106 untreated cells.  
CSP ELISA – Maxisorb immunoplates were coated with a monoclonal antibody (mAb) to CSP ((sc-
136468) Santa Cruz) and blocked with 5% milk powder. Samples were added and bound CSP was detected 
using rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz) followed by a biotinylated anti-rabbit IgG, 
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extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured 
at 405 nm. Samples were expressed as “units CSP” where 100 units was the amount of CSP in 106 control 
cells.  
Isolation of synaptosomes -  Synaptosomes were prepared on a discontinuous Percoll gradient based on 
methods previously described (Thais et al., 2006). Briefly, 106 neurons were homogenized at 4 °C in 1 ml 
of SED solution (0.32 M sucrose, 50 mM Tris-HCl pH 7.4, 1 mM EDTA and 1 mM dithiothreitol) and 
centrifuged at 1000 × g for 5 minutes. The supernatant was transferred to a 4-step gradient of 3, 10, 15 and 
23% Percoll in SED solution and centrifuged at 16,000 × g for 30 minutes at 4oC. The synaptosomes were 
collected from the interface of the 15% and 23% Percoll steps and washed twice at 4oC. Freshly prepared 
synaptosomes were pre-treated with drugs for 1 hour and incubated with peptides for 1 hour. 
Synaptic vesicle recycling - The uptake of the fluorescent dye FM1-43 (Molecular probes) into synaptic 
recycling vesicles was used to determine synaptic activity. Treated synaptosomes were pulsed with 5 μM 
FM1-43 and 1 μM ionomycin (Sigma) for 5 minutes, washed 3 times in ice cold PBS and homogenised in 
methanol. Extracts were transferred into 96 well black microplates (Sterilin) and fluorescence was 
measured in a spectrophotometer using excitation at 480 nm and measuring emission at 625 nm. Samples 
were expressed as “% fluorescence” where 100% fluorescence was defined as the amount of fluorescence 
in control synaptosomes.  
Isolation of lipid rafts (detergent-resistant membranes) - These membranes were isolated by their 
insolubility in non-ionic detergents. Briefly, synaptosomes were homogenised in an ice-cold buffer 
containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed protease 
inhibitors and nuclei and large fragments were removed by centrifugation (300 x g for 5 minutes at 4oC). 
The post nuclear supernatant was incubated on ice (4oC) for 1 hour and centrifuged (16,000 x g for 30 
minutes at 4oC). The supernatant was reserved as the detergent soluble membrane while the insoluble pellet 
was homogenised in an extraction buffer containing 10 mM Tris-HCL, pH 7.4, 150 mM NaCl, 10 mM 
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EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease inhibitors at 106 
cells/ml, centrifuged (10 minutes at 16,000 x g) and the soluble material was reserved as the DRM fraction.  
 
Sucrose density gradients - Synaptosomes were homogenised in a buffer containing 250 mM sucrose, 10 
mM Tris-HCl (pH 7.4), 1 mM EGTA, mixed protease inhibitors and 1 mM dithiothreitol. Particulate 
membrane fragments and nuclei were removed by centrifugation (1000 x g for 5 min). Membranes were 
washed by centrifugation at 16,000 x g for 10 minutes at 4oC and suspended in an ice-cold buffer containing 
1% Triton X-100, 10 mM Tris-HCl pH 7.2, 150 mM NaCl, 10 mM EDTA. 5–40% sucrose solutions were 
prepared and layered to produce a gradient. Solubilised membranes were layered on top and centrifuged at 
50000 x g for 18 hours at 4°C. Serial 1 ml aliquots were collected from the bottom of gradients.  
 
cPLA2 ELISA/activated cPLA2/PGE2 measurement - The amounts of cPLA2 in extracts was measured 
by ELISA as described (Bate and Williams, 2011). Maxisorb immunoplates were coated with 0.5 µg/ml of 
mouse mAb anti-cPLA2 (clone CH-7 - Upstate) and blocked with 5% milk powder in PBS + 0.1% tween 
20 (PBST). Samples were incubated for 1 hour and the amount of bound cPLA2 was detected using a goat 
polyclonal anti-cPLA2 (Santa-Cruz Biotech) followed by biotinylated anti-goat IgG, extravidin-alkaline 
phosphatase and 1 mg/ml pNPP solution. Absorbance was measured at 405 nm and the amount of cPLA2 
protein expressed in units, 100 units = amount of cPLA2 in control preparations. The activation of cPLA2 
is accompanied by phosphorylation of the 505 serine residue which creates a unique epitope and can be 
measured by ELISA (Bate et al., 2010). To measure the amount of activated cPLA2, an ELISA using a mAb 
(anti-cPLA2, clone CH-7) combined with rabbit polyclonal anti-phospho-cPLA2 (Cell Signalling 
Technology) followed by biotinylated anti-rabbit IgG (Sigma), extravidin-alkaline phosphatase and 1mg/ml 
pNPP solution. Absorbance was measured on a microplate reader at 405 nm. Results were expressed as 
“units activated cPLA2” (100 units = amount of activated cPLA2 in control preparations). The amounts of 
PGE2 in synaptosomes were determined using a competitive enzyme immunoassay kit (Amersham Biotech, 
Amersham, UK) according to the manufacturer's instructions.    
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Aβ42 ELISA –Nunc Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) (Covance) in 
carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween and samples were 
applied. The detection antibody was an Aβ42 selective rabbit mAb BA3-9 (Covance) followed by 
biotinylated anti-rabbit IgG and extravidin alkaline phosphatase (Sigma). Bound Aβ42 was visualised by 
addition of 4-nitrophenol phosphate solution. Absorbance was measured at 405 nm and compared to 
titrations of synthetic Aβ1-42 (Bachem). 
 
Cholesterol content - The amounts of cholesterol in samples were measured using the Amplex Red 
cholesterol assay kit (Invitrogen), according to the manufacturer’s instructions. Briefly, cholesterol is 
oxidised by cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 
10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin, which 
is measured by excitation at 550 nm and emission detection at 590 nm. By performing the assay in the 
presence or absence of cholesterol esterase (50 units/ml) (Sigma) the assay can also determine the amounts 
of esterified cholesterol within samples. 
 
Drugs – VPA and decanoic acid was obtained from Sigma. PIA was obtained from Ukrogsyntez Ltd. Stock 
solutions were dissolved in ethanol or di-methyl sulphoxide (DMSO) and diluted in medium to obtain final 
working concentrations. Vehicle controls consisted of equal dilutions of ethanol or DMSO.  
 
Statistical Methods - Differences between treatment groups were assessed using Student’s paired t tests. 
Error bars are standard deviation (SD). Correlations were bivariate analysis and significance was set at 
0.01% 
 
Results 
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Brain extracts contain toxic Aβ - Synaptic degeneration is a prominent feature of the early stages of 
Alzheimer’s disease (Reddy et al., 2005) and is thought to be caused by a toxic soup of Aβ peptides 
including Aβ40, Aβ42 and Aβ43 (Benilova et al., 2012). To develop an in vitro model for synaptic loss, we 
employed brain extracts derived from a patient with Alzheimer’s disease containing a mixture of Aβ 
monomers, dimers and trimers, as characterised by Western blot (Figure 1A) and by size exclusion 
chromatography (Figure 1B). We then examined the effect of increasing concentrations of Aβ over a 24 
hour period on synapses from cultured primary mouse cortical neurons. Addition of increasing amounts of 
Aβ-containing brain extracts triggered the loss of synaptophysin (Figure 1C) and CSP (Figure 1D) and 
other synaptic proteins including VAMP-1 and synapsin-1 indicative of synapse damage (Figure 1E). These 
effects occurred in the absence of any neuronal death as measured by thiazolyl blue tetrazolium (101% cell 
survival ± 6 compared with 100% ± 5, n=6, P=0.6) and there was no loss of caveolin from treated neurons. 
Immunodepletion of brain extract with mAb G48 reduced concentrations of both Aβ40 (4.9 nM ± 0.3 
compared with 0.3 nM ± 0.3 nM, n=9, P<0.01) and Aβ42 (1.42 nM ± 0.16 to 0.11 nM ± 0.1 nM, n=9, 
P<0.01). Immunodepleted brain extract did not cause any significant loss of synaptophysin or CSP from 
neurons indicating that Aβ was the synaptotoxic entity in these preparations. Mock-depletions, with control 
mouse IgG, did not affect the concentration of either Aβ40 (4.9 nM ± 0.3 compared with 4.74 nM ± 0.9, 
n=9, P=0.58) or Aβ42 (1.42 nM ± 0.16 compared with 1.38 ± 0.37 nM, n=9, P=0.48), nor did they affect the 
brain extract-induced reduction of neuronal synaptophysin or CSP. 
 
Aβ, αSN and prion-induced synapse damage was reduced by VPA and PIA – To investigate a role of 
VPA on cultured neurons, synaptophysin and CSP levels were measured in neurons in the absence or 
presence of increasing amounts of Aβ-containing brain extracts for a 24 hour period. Pre-treatment of 
neurons with VPA (10 μM, 1 hour) did not significantly alter the amounts of synaptophysin (Figure 2A) or 
CSP (Figure 2B) in neurons, indicating that VPA did not affect synapses in the absence of pathogenic 
signalling. However, pre-treatment of neurons with VPA (10 μM) for 1 hour prior to incubation with 
increasing concentrations of Aβ-containing brain extracts for a 24 hour period, gave rise to a dose-
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dependent neuroprotective effect in blocking the loss of synaptophysin (Figure 2A) or CSP (Figure 2B). 
This effect was also shown with a structurally related VPA analogue, propylisopropylacetic acid (PIA), but 
not with a straight-chain fatty acid, decanoic acid (DA). Neither PIA, nor decanoic acid affected 
synaptophysin or CSP concentrations in the absence of Aβ (supplementary data, Table 1). The effects of 
VPA and PIA were dose-dependent (Figure 2C).  
Other neurodegenerative diseases including Lewy body dementia, Parkinson’s disease and prion diseases 
are also associated with synaptic loss (Kramer and Schulz-Schaeffer, 2007). In these diseases, aggregated 
αSN and the disease-associated, prion-derived peptide (PrP82-146) cause synapse damage. To examine a 
role for VPA and PIA in protection against these neurodegenerative-associated proteins, cultured neurons 
were initially exposed to αSN and the prion-derived peptide PrP82-146 for a 24 hour period, and synaptic 
protein loss was monitored. We show increasing concentrations of αSN also triggered the loss of 
synaptophysin (Figure 3A) and CSP (Figure 3B) in cultured neurons. However, pre-treatment with either 
VPA or PIA, but not decanoic acid (all at 10 μM) for 1 hour prior to αSN exposure, partially protected 
against the loss of synaptophysin (Figure 3A) or CSP (Figure 3B). Similarly, increasing concentrations of 
PrP82-146 for a 24 hour period also triggered the loss of synaptophysin (Figure 3A) and CSP (Figure 3B), 
and pre-treatment with VPA or PIA, but not 10 μM decanoic acid (both at 10 μM) for 1 hour prior to PrP82-
146 exposure also partially protected against the loss of synaptophysin (Figure 3C) or CSP (Figure 3D). In 
contrast, pre-treatment with VPA, PIA or decanoic acid (all at 10 μM) did not alter the loss of synaptophysin 
or CSP-induced by phospholipase A2-activating peptide (PLAP) (Figure 3E &F) suggesting a specificity of 
effect relating to neurodegenerative protein function.  
Aβ, αSN and prion-induced reduction in synaptic vesicle recycling was reduced by VPA and PIA - 
The fluorescent dye FM1-43 is used to visualise synaptic vesicles uptake in confocal microscopy (Klingauf 
et al., 1998). This system was modified to enable quantification of FM1-43 uptake into synaptosomes 
(multiple synapses). We showed that ionomycin (a calcium ionophore that stimulates neurotransmitter 
release and synaptic vesicle recycling) caused the uptake of FM1-43 by synaptosomes (Figure 4A) 
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consistent with increased vesicle recycling. Using this approach, vesicle recycling was not affected by pre-
treating synaptosomes with VPA, PIA or decanoic acid (all at 10 μM) in the absence of Aβ.  However, the 
addition of Aβ-containing brain extract to synaptosomes reduced recycling in a dose-dependent manner 
(Figure 4B) and Aβ-depleted brain extract did not affect recycling, indicating that Aβ was responsible for 
this effect. The inhibitory effect of Aβ was reduced in synaptosomes pre-treated with VPA or PIA for 1 
hour, but was not affected by decanoic acid (all at 10 μM; Figure 4C). Similarly, pre-treatment of 
synaptosomes with VPA or PIA, but not decanoic acid significantly reduced the inhibitory effects of PrP82-
146 (Figure 4D) and αSN (Figure 4E) on the vesicle recycling. These data suggest that inhibition of synaptic 
vesicle release provides a common response to multiple neurodegenerative disease-linked proteins in vitro, 
and that this common effect is reduced by pre-treatment with VPA or PIA. 
Aβ42 to binding to synapses was not affected by VPA and PIA – The observations that Aβ accumulated 
within synapses prior to synapse damage (Lacor et al., 2004) raised the possibility that VPA might prevent 
synapse damage by reducing the accumulation of Aβ within synapses. To investigate this, we pre-treated 
neurons with VPA (10 μM) for 1 hour and incubated with 10 nM Aβ42, the concentration of Aβ42 found in 
synaptosomes was not significantly altered (2.9 nM Aβ42 ± 0.7 compared with 3.2 nM Aβ42 ± 0.6, n=9, 
P=0.5). Similar results were obtained with PIA (10 μM), since it did not significantly affect the binding of 
Aβ42 to synaptosomes (3.1 nM Aβ42 ± 0.6 compared with 3.2 nM Aβ42 ± 0.6, n=9, P=0.5).  
Aβ, αSN and prion-induced hyperactivation of cPLA2 at the synapse was reduced by VPA and PIA - 
Several studies suggest that aberrant activation of cPLA2 is involved in Aβ-induced synapse damage. For 
example, Aβ peptides activate PLA2 (Shelat et al., 2008) and inhibition of cPLA2 prevented Aβ-induced 
synapse damage in vitro (Bate et al., 2010). In addition, cPLA2 inhibitors ameliorate the cognitive decline 
seen in a transgenic model of Alzheimer’s disease (Sanchez-Mejia et al., 2008). We therefore investigate 
the activation of cPLA2 in synapses. The addition of Aβ-containing brain extracts, but not Aβ-depleted 
brain extract, caused a dose-dependent increase in the amounts of activated cPLA2 (Figure 5A). Although 
VPA, PIA or decaonoic acid (all at 10 μM) did not affect the amounts of cPLA2 protein or activated cPLA2 
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within synaptosomes (supplementary data, Table 2) the Aβ-induced activation of cPLA2 in synaptosomes 
was reduced by 1 hour pre-treatment with VPA or PIA, but not with decanoic acid (all at 10 μM). The 
effects of VPA and PIA upon Aβ-induced activation were dose-dependent and there was no observable 
difference in their efficacy (Figure 5B). Similarly, pre-treatment of synaptosomes with either VPA or PIA 
(both at 10 μM) reduced αSN (Figure 5C) and PrP82-146 (Figure 5D)-induced activation of cPLA2. In 
contrast, pre-treatment with VPA or PIA (both at 10 μM) did not affect the PLAP-induced activation of 
synaptic cPLA2 (Figure 5E) indicating that these drugs did not have a direct effect upon this enzyme. The 
activation of cPLA2 is the first step in the production of prostaglandins (PG) including PGE2 which causes 
synapse damage in cultured neurons (Bate et al., 2010). Here we show that pre-treatment of synaptosomes 
with either VPA or PIA (both at 10 μM) reduced Aβ and αSN-induced PGE2 production, but had no effect 
upon PLAP-induced PGE2 production (Figure 5F). These data suggest that activated cPLA2 activity 
provides a common response to multiple neurodegenerative disease-linked proteins, and that this common 
effect is reduced by pre-treatment with VPA or PIA.  
The activation of cPLA2 is accompanied by its migration to specific membranes utilizing a Ca2+-dependent 
lipid binding domain (Nalefski et al., 1994). To investigate cPLA2 localisation in lipid rafts as a cause of 
enhanced activity, sucrose density gradients generated from synaptosomes in the presence or absence of 
Aβ (Figure 6A). Lipid rafts were defined by solubility in triton X-100. The addition of Aβ-containing, but 
not Aβ-depleted brain extract, increased the amounts of cPLA2 within lipid rafts.  The addition of Aβ caused 
a dose-dependent increase in cPLA2 in lipid rafts (Figure 6B). There was a significant correlation between 
the amounts of cPLA2 in lipid rafts and the amounts of activated cPLA2 in synaptosomes incubated with 
brain extracts containing between 1 and 0.125 nM Aβ42 (Figure 6C). VPA, PIA and decanoic acid alone 
did not affect the amounts of cPLA2 found within rafts (supplementary data, Table 2). In synaptosomes pre-
treated with either VPA or PIA (both at 10 μM), less cPLA2 was found within lipid rafts following the 
addition of Aβ-containing brain extract (Figure 6D). This data suggest that the Aβ-dependent increase in 
lipid raft-localised cPLA2 localisation is blocked by the treatment of VPA and PIA.  
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Aβ-induced increase in synaptic cholesterol is prevented VPA and PIA - The amount of cholesterol in 
cell membranes is a critical factor involved in both lipid raft formation (Pike, 2004) and in 
neurodegeneration (Maxfield and Tabas, 2005) and Aβ has been shown to regulate cholesterol homeostasis 
through an unknown mechanism (Liu et al., 1998). We therefore determined the cholesterol concentrations 
in synaptosomes following the addition of Aβ-containing brain extract. Increasing concentration of Aβ 
caused a dose-dependent increase in synaptic cholesterol (Figure 7A) and a corresponding reduction in 
synaptic cholesterol esters (Figure 7B). There was a significant correlation between the increased 
concentrations of cholesterol and reduced concentrations of cholesterol esters in synaptosomes incubated 
with brain extract containing between 1 nM and 0.125 nM Aβ42, Pearson’s coefficient= -0.931, P<0.01 
(Figure 7C). These results suggests that Aβ acts through the cholesterol ester cycle, activating cholesterol 
ester hydrolase enzymes that release biologically active cholesterol into the membrane from stores of 
cholesterol esters in lipid droplets (Figure 7E). There was also a significant correlation between the 
concentrations of cholesterol and activated cPLA2 in synaptosomes incubated with brain extract containing 
between 1 nM and 0.125 nM Aβ42, Pearson’s coefficient= -0.734, P<0.01, (Figure 7D) suggesting that 
cholesterol concentrations affect the Aβ-induced activation of cPLA2. These data suggest that Aβ acts to 
alter cholesterol ester hydrolases activity to modify cPLA2 activity by lipid raft localisation.  
Since we have shown VPA and PIA reduce Aβ-dependent cPLA2 activation, we then investigated a role for 
these compounds in cholesterol recycling. While the addition of VPA or PIA or decanoic acid (all at 10 
μM) did not affect the amounts of cholesterol in synaptosomes, pre-treatment of synaptosomes with VPA 
or PIA significantly reduced the Aβ-induced increase in cholesterol in synaptosomes (Figure 8A). Similarly, 
the Aβ-induced reduction in cholesterol esters was blocked by pre-treatment with VPA or PIA (both at 10 
μM; Figure 8B).  
 
 
 16 
Discussion  
 
The discovery of compounds that reduce synapse damage is a rational strategy to reduce clinical symptoms 
in neurodegenerative diseases including prion diseases, Alzheimer’s disease and Parkinson’s disease.  In 
this study we demonstrate that VPA and PIA protected cultured neurons against synapse damage induced 
by the neurotoxic peptides Aβ, PrP82-146 and αSN. Neuroprotection was associated with the regulation of 
cholesterol and inhibition of cPLA2, hyperactivation of which leads to synapse degeneration and memory 
defects (Bate et al., 2010; Sanchez-Mejia et al., 2008). This study used 2 models of synapse damage; firstly 
the loss of synaptic proteins from cultured neurons and secondly the inhibition of fluorescent FM1-43 
uptake into synaptosomes as an indicator of the synapse vesicle recycling that is necessary for normal 
neurotransmission. The loss of synaptic proteins from neurons indicated synapse degeneration and the 
disruption in synaptic vesicle recycling demonstrated synapse dysfunction. Both these effects were apparent 
at concentrations of neurotoxic peptides that did not cause neuronal death. In this respect we have sought 
to replicate the early stages of disease where there is significant synapse dysfunction/damage but without 
the extensive loss of neurons that occurs during the latter stages of disease. 
 
Our date suggests that VPA may attenuate the Aβ-induced synapse damage that underlies the dementia 
observed in Alzheimer’s disease patients. Similarly, VPA protected neurons against synapse damage 
induced by αSN, aggregates of which accumulate in synapses during Parkinson’s disease and Lewy body 
dementia (Kramer and Schulz-Schaeffer, 2007) and the prion-derived peptide PrP82-146. We demonstrate 
a mechanism for this neuroprotective effect through inhibiting hyperactivation of cPLA2 by these 
neurotoxic peptides. Consistent with this mechanism, VPA has been reported to show PLA2 inhibitory-like 
activity (Bosetti et al., 2003; Elphick et al., 2012; Rapoport and Bosetti, 2002), in addition to inhibiting 
phosphoinositide turnover (Chang et al., 2012) and histone deactylase activity (Phiel et al., 2001). PIA is 
thought to have greater therapeutic potential as it does not inhibit histone deacteylase (Eyal et al., 2005), an 
activity associated with teratogenic effects (Jentink et al., 2010). Although a direct mechanism of action 
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has been recently reported for PIA, through an inhibition of acyl-CoA synthetase (Modi et al., 2013), this 
effect occurs with a Ki of 11.4 mM, that is around 1000-fold higher than effective concentrations reported 
here. PIA has also been shown to strongly reduce fatty acid release (Elphick et al., 2012) consistent with 
an indirect effect on cPLA2 activity shown here. Decanoic acid was used in this study, since like VPA, it 
has also been reported to inhibit phosphoinositide turnover in relation to seizure control (Chang et al., 2012), 
although again at higher concentrations than used in this study, thus it appears that VPA and PIA exert 
different effects on neuroprotection that decanoic acid at these concentrations.  Neither VPA nor PIA 
protected cultured neurons against synapse damage triggered by PLAP indicating that VPA and PIA affect 
specific pathways that are activated by neurotoxic peptides.  
 
VPA has been reported to reduce Aβ production (Qing et al., 2008b; Su et al., 2004) and attenuate neuronal 
loss in a murine transgenic model of Alzheimer’s disease (Long et al., 2013). Our study showed that neither 
VPA nor PIA significantly altered the amounts of Aβ42 that bound to synapses. The observation that Aβ 
can accumulate within synapses without causing synapse damage indicates that synapse damage occurs via 
activation of specific pathways, rather than a direct effect of Aβ itself.  Prior studies had demonstrated the 
importance of cPLA2 in Alzheimer’s disease, pharmacological inhibition of cPLA2 protected neurons 
against Aβ-induced synapse damage (Bate et al., 2010) and inhibited cognitive impairment in a murine 
model of Alzheimer’s disease (Sanchez-Mejia et al., 2008). Others have reported that VPA and PIA alter 
arachidonic acid metabolism (Bazinet et al., 2006) and here we showed that VPA and PIA, but not decanoic 
acid, reduced the activation of synaptic cPLA2 by Aβ, PrP82-146 or αSN. It was notable that the 
concentrations of VPA and PIA required to inhibit Aβ-induced activation of synaptic cPLA2 were similar 
to those that reduced Aβ-induced synapse damage, observation supporting the direct role of activated cPLA2 
in Aβ-induced synaptotoxicity. The activation of cPLA2 is critical for the formation of bioactive lipids 
including prostaglandins and PAF. The neurotoxic peptides used in this study activates cPLA2 leading to 
the production of PGE2 which caused synapse damage (Bate et al., 2010) and are raised in the cerebrospinal 
fluid of patients with probable Alzheimer’s disease (Montine et al., 1999).  
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Neither VPA nor PIA affected the activation of cPLA2 by PLAP suggesting that they did not have a direct 
effect upon the enzyme. The activation of cPLA2 is accompanied by its migration to specific membranes 
utilizing a Ca2+-dependent lipid-binding domain (Nalefski et al., 1994). Here we show that Aβ causes cPLA2 
to be targeted to lipid rafts and that in synaptosomes there was a significant correlation between the % of 
cPLA2 in rafts and activation of cPLA2 following the addition of Aβ. The recruitment of signalling proteins 
to specific compartments is an emerging concept in the regulation of cell activation. The observations that 
Aβ is found within lipid rafts (Williamson et al., 2008) and the Aβ-induced activation of cPLA2 is 
cholesterol sensitive (Bate and Williams, 2007) suggests that the formation of specific lipid rafts is 
necessary for Aβ-induced activation of cPLA2 and synapse degeneration.  Critically, pre-treatment with 
VPA or PIA reduced the Aβ-induced translocation of cPLA2 to rafts. 
 
It should be noted that cPLA2 and the products of its activation including PAF and prostaglandins are 
involve in the normal function of the synapse. Both PGE2 and PAF have both been implicated in the 
induction of long-term potentiation and memory formation (Chen and Bazan, 2005). Our contention is that 
it is Aβ-induced aberrant activation of cPLA2 that leads to synapse degeneration. Therefore, the inhibition 
of cPLA2 by VPA and PIA may be beneficial under these conditions. However, long term VPA treatment 
is associated with impairment of hippocampal synaptic plasticity (Sgobio et al., 2010) and in vitro 1 mM 
VPA reduced long term potentiation in hippocampal slices (Chang et al., 2010) indicating that VPA and 
PIA may also reduce activation of cPLA2 in normal synapses. 
 
Aβ has been shown to affect cholesterol homeostasis and in these neurons Aβ increased cholesterol 
concentrations in synaptosomes; an effect consistent with observations of increased concentrations of 
cholesterol in Aβ positive synapses in the cortex of Alzheimer’s patients (Gylys et al., 2007). The Aβ-
induced increase in cholesterol may be significant in that cholesterol an essential role in their formation and 
function of lipid rafts (Pike, 2004) and there was a significant correlation between the increase in cholesterol 
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and activated cPLA2 in response to Aβ. Notably, VPA and PIA did not affect cholesterol concentrations in 
control synaptosomes but both reduced the Aβ-induced increase in cholesterol. Our studies showed that the 
Aβ-induced increase in synaptic cholesterol was accompanied by a reduction in cholesterol esters indicating 
that Aβ activated cholesterol ester hydrolase. The observation that VPA and PIA prevented the Aβ-induced 
reduction in concentrations of cholesterol esters suggests that these drugs inhibit cholesterol ester hydrolase.  
 
Conclusion 
 
In summary we report that VPA and PIA protected cultured neurons against the synapse damage that was 
induced by Aβ, αSN or PrP82-146, neurotoxic peptides associated with disease progression in Alzheimer’s, 
Parkinson’s and prion disease. Our results are consistent with the hypothesis that VPA and PIA inhibit the 
peptide-induced activation of cPLA2, hyperactivation of which leads to synapse damage. These drugs do 
not appear to have a direct effect upon cPLA2, rather they affected the membrane micro-environment in 
which peptides activate cPLA2, inhibiting the release of cholesterol that is required for a stable signalling 
platform. These studies suggest that VPA and PIA may be able to reduce synapse damage and ameliorate 
pathology in Alzheimer’s, Parkinson’s and prion diseases. 
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Figure Legends  
 
Figure 1. Soluble Aβ triggers synapse damage in neurons - (A) Immunoblot showing Aβ monomers (M), 
dimers (D) and trimers (T) in brain extract (1) and Aβ-depleted brain extract (2). (B) Aβ monomers (M), 
dimers (D) and trimers (T) eluted from a Superdex 75 PC column (separates proteins ranging from 3 kDa 
to 70 kDa) loaded with a soluble brain extract. Values are means of duplicates. The amounts of 
synaptophysin (C) and CSP (D) in neurons incubated with brain extracts (●), Aβ-depleted brain extracts 
(▲) or mock-depleted brain extracts (∆). Values are means ± SD from triplicate experiments performed 4 
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times, n=12. (E) Immunoblots showing the amounts of synaptophysin, CSP synapsin-1, VAMP-1 and 
caveolin in neurons incubated with brain extract as shown.  
 
Figure 2 - Synapse damage induced by Aβ is reduced by VPA and PIA - The amounts of (A) 
synaptophysin and (B) CSP in neurons pre-treated with control medium (●), 10 μM VPA (○), 10 μM PIA 
(□) or 10 μM decanoic acid (■) and incubated with brain extracts containing Aβ42 as shown. Values are 
means ± SD from triplicate experiments performed 4 times, n=12. (C) The amounts of synaptophysin in 
neurons pre-treated with VPA (●), PIA (□) or decanoic acid (■) and incubated with brain extract containing 
2 nM Aβ42. Values are means ± SD from triplicate experiments performed twice, n=6. 
 
Figure 3. Synapse damage induced by αSN and PrP82-146 is reduced by VPA and PIA – The amounts 
of synaptophysin (A) and CSP (B) in neurons pre-treated with control medium (●), 10 μM VPA (○), 10 μM 
PIA (□) or 10 μM decanoic acid (■) and incubated with αSN as shown. The amounts of synaptophysin (C) 
and CSP (D) in neurons pre-treated with control medium (●), 10 μM VPA (○), 10 μM PIA (□) or 10 μM 
decanoic acid (■) and incubated with PrP82-146 as shown. The amounts of synaptophysin (E) and CSP (F) 
in neurons pre-treated with control medium (●), 10 μM VPA (○), 10 μM PIA (□) or 10 μM decanoic acid 
(■) and incubated with PLAP as shown. All values are means ± SD from triplicate experiment performed 
4 times, n=12. 
 
Figure 4. Synaptic vesicle recycling is inhibited by Aβ, αSN and PrP82-146 and is rescued by VPA 
and PIA – (A) The amounts of FM1-43 in synaptosomes pre-treated with control medium  (●), 10 μM 
VPA (○), 10 μM PIA (□) or 10 μM decanoic acid (■) and pulsed with ionomycin as shown (●). Values are 
mean % fluorescence (100%=maximum fluorescence in synaptosomes). (B) The amounts of FM1-43 in 
synaptosomes incubated with brain extract (●), Aβ-depleted brain extract (▲) or mock-depleted brain 
extract (∆) and pulsed with ionomycin. The amounts of FM1-43 in synaptosomes pre-treated with control 
medium (●), 10 μM VPA (○), 10 μM PIA (□) or 10 μM decanoic acid (■), incubated with brain extract 
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containing Aβ42 as shown (C), PrP82-146 (D) or αSN (E) and pulsed with ionomycin. All values are means 
± SD from triplicate experiments performed 3 times, n=9.   
 
Figure 5. Induced activation of synaptic cPLA2 by Aβ, αSN and PrP82-146 is reduced by VPA and 
PIA (A) The amounts of activated cPLA2 in synaptosomes pre-treated with control medium (●), 10 μM 
VPA (○), 10 μM PIA (□) or 10 μM decanoic acid (■) and incubated with brain extract containing Aβ42 as 
shown. (B) The amount of activated cPLA2 in synaptosomes pre-treated with VPA (○), PIA (□) or decanoic 
acid (■) and incubated with brain extract containing 2 nM Aβ42. The amounts of activated cPLA2 in 
synaptosomes pre-treated with control medium (●), 10 μM VPA (○), 10 μM PIA (□) or 10 μM decanoic 
acid (■) and incubated with (C) αSN or (D) PrP82-146 as shown. (E) The amounts of activated cPLA2 in 
synaptosomes pre-treated with control medium (●), 10 μM VPA (○), 10 μM PIA (□) or 10 μM decanoic 
acid (■) and incubated PLAP as shown. All values are means ± SD, from triplicate experiments performed 
3 times, n=9. (F) The concentrations of PGE2 in synaptosomes pre-treated with control medium (■), 10 μM 
VPA (□) or 10 μM decanoic acid (striped bar) and incubated with brain extract containing 2 nM Aβ42, 500 
nM αSN or 500 nM PLAP. Values are means ± SD, n=6. *=PGE2 significantly less than in control 
synaptosomes incubated with peptides.  
 
Figure 6. Aβ-induced translocation of cPLA2 into rafts is reduced by VPA and PIA – (A) The amount 
of cPLA2 in fractions from control synaptosomes (○) or synaptosomes incubated with brain extract 
containing 1 nM Aβ42 (●). (B) The amounts of cPLA2 in lipid rafts derived from synaptosomes incubated 
with control medium (□) or brain extract containing Aβ42 as shown. (C) There was a significant correlation 
between the amounts of raft cPLA2 and activated cPLA2 in synaptosomes incubated with brain extract 
containing Aβ42 (1 nM to 0.6 nM), Pearson’s coefficient=0.927, P<0.01. (D) The amounts of cPLA2 in lipid 
rafts derived from synaptosomes pre-treated with control medium (□), 10 μM VPA (■), 10 μM PIA (striped 
bar) or 10 μM decanoic acid (DA) (hatched bar) and incubated with brain extract containing 1 nM Aβ42. 
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All values are means ± SD, from triplicate experiments performed 3 times, n=9. *=amounts of raft cPLA2 
significantly less than in control synaptosomes incubated with Aβ. 
 
Figure 7. Aβ-induces increased synaptic cholesterol and reduced cholesterol esters – The 
concentrations of cholesterol (A) and cholesterol esters (B) in synaptosomes incubated with control medium 
(□) or brain extract containing Aβ42 as shown (■). Values are means ± SD from triplicate experiments 
performed 4 times (n=12). *=cholesterol significantly higher than in control synaptosomes. **=cholesterol 
esters significantly lower than in control synaptosomes. (C) There was a significant inverse correlation 
between the concentrations of cholesterol and cholesterol esters in synaptosomes incubated with brain 
extract containing Aβ42 (1 nM to .125 nM), Pearson’s coefficient= -0.931, P<0.01. (D) There was a 
significant correlation between the concentrations of cholesterol and amounts of activated cPLA2 in 
synaptosomes incubated with brain extract containing Aβ42 (1 nM to .125 nM), Pearson’s coefficient= -
0.734, P<0.01. (E) Schematic showing the cholesterol ester cycle and the proposed release of synaptic 
cholesterol via Aβ-induced activation of cholesterol ester hydrolases (CEH). 
 
Figure 8. Aβ-induced changes in synaptic cholesterol is reduced by VPA and PIA – The concentrations 
of cholesterol (A) and cholesterol esters (B) in synaptosomes pre-treated with control medium, 10 μM VPA, 
10 μM PIA or 10 μM decanoic acid (DA) and incubated with control medium (□) or brain extract containing 
1 nM Aβ42  (■). *=cholesterol significantly lower than in control synaptosomes incubated with Aβ. 
**=cholesterol esters significantly higher than in control synaptosomes incubated with Aβ.  
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